Osteosarcoma Answers and Assistance
OSI Connect is our free, easy-to-use resource for patients who have been diagnosed with osteosarcoma, or suffered a relapse after initial treatment. These events are devastating and overwhelming, and start a desperate pursuit to gain knowledge and understanding. Often people turn first to the internet but encounter an avalanche of search results with no way to assess their accuracy, quality, or applicability. This resource helps patients and their families find answers to their questions from an experienced, knowledgeable osteosarcoma physician about all aspects of the disease, including treatment, possible side effects, and advice for getting the most out of your visits with your treating physician. Se habla español.
A Clinical Trial
The Osteosarcoma Institute is pleased to connect interested parties with CareBox, a free and confidential trial matching service that will help guide you through a search and referral process to find a clinical trial that may be right for you. This matching system shortens the clinical trial search process from weeks to minutes, helping users identify clinical trials with eligibility criteria that match a patient’s specific diagnosis, stage, symptoms, and treatment history. Fill out your contact information below, and a Clinical Trial Navigator will call you within one business day. Se habla Español.
Partnering for Progress
Your osteosarcoma science fund with our support and infrastructure
Here at the Osteosarcoma Institute, we care about progress, not credit. We believe the more people working on the problem, the better. We establish partnerships with like-minded families and foundations wishing to co-fund osteosarcoma research studies and trials with the assistance of our organization. Raising funds in honor of a loved one is a major endeavor. We make it easier by handling many of the logistics. To learn more about Partnering for Progress, please contact our Development Manager, Vanessa Peterson, at email@example.com.
Miles of Hope Fund
In 2022, Ingrid and David Hartz established the Miles of Hope Fund at the OSI in honor of their teenage son, Miles. Sadly, Miles passed away from osteosarcoma at the age of 17 on Sunday, June 25, 2023 after a five year battle against the disease. The Miles of Hope Fund has raised more than $183,000 (as of September 2023). In 2022, the Hartz family chose to support osteosarcoma research conducted by Dr. Richard Gorlick at MD Anderson Cancer Center. They are motivated to help support the most promising clinical trials and science to fight osteosarcoma and will select a new effort to support in 2023. Support their fight by making a donation to their fund today.
Team Lydia Osteosarcoma Science Fund
The Team Lydia Osteosarcoma Science Fund at the OSI was established in 2022 by Lydia Alwan‘s parents, Jessica and Steve. Lydia was initially diagnosed with osteosarcoma in the spring of 2019 and has been cancer free for two years! Her family and friends have helped raise more than $59,000 to date for osteosarcoma research (as of September 2023) through online giving and the inaugural Team Lydia Give Kids a Shot Charity Golf Tournament that took place on September 22, 2023!
The Scott Shockley Foundation
The Scott Shockley Foundation was established in memory of Scott Shockley, a cherished son, brother and friend who lost his battle with osteosarcoma in July 2013. Scott’s parents, Terriann and Steve, are working directly with the Osteosarcoma Institute to co-fund promising research for this terrible disease. In 2023, they decided to select an immunotherapy study for high-risk osteosarcoma conducted by Dr. Jason Yustein at Emory University.
Lizzy’s Osteosarcoma Science Fund
In 2020, the Osteosarcoma Institute partnered with Lizzy’s Walk of Faith Foundation to establish Lizzy’s Osteosarcoma Science Fund at the OSI. Together, we have raised more than $126,000 (as of September 2023) in honor of Lizzy Wampler. Lizzy’s Fund is being applied towards a breakthrough liquid biopsy study selected by Lizzy’s parents and the founders of LWOF Foundation, Jennifer and John Wampler. This study is being conducted by Dr. Brian Crompton at the Dana-Farber Cancer Institute.
Fabulous Faith’s Foundation
In 2013, 10-year-old Faith Rose Lautzenheiser entered heaven after her 10-month battle with osteosarcoma. In 2022, Fabulous Faith’s Foundation (FFF) generously provided a $35,000 donation for two osteosarcoma research projects, with one named for Faith, the foundation’s inspiration. They selected Dr. Sweet-Cordero’s research on the activation of STING as a therapeutic strategy in osteosarcoma to name after Faith. Learn more.
#TeamIzzy’s Osteosarcoma Science Fund
The Osteosarcoma Institute joined forces with osteosarcoma patient, Izzy Martin, and her family to start a fund in her name in 2021. Together, we have raised more than $392,000 (as of September 2023), which will be applied to a breakthrough clinical trial or study in osteosarcoma this year. Izzy’s mom, Christine, shares, “Izzy’s wish is that one day, no child will have to go through what she did.”
The Beautifully Flawed Retreat was designed to unite and inspire young women ages 14-25 who face limb differences or the loss of a limb; to uncover the beauty in every story. It includes expert advice, instruction and practical health and wellness tips that specifically focus on limb differences from onsite doctors, trainers and nutrition specialists.
Osteosarcoma Now was developed with the sole purpose of supporting osteosarcoma patients and their families throughout their cancer journey, wherever they live in the world. Their curated clinical trial database gives patients the tools and information to explore new treatment options and make decisions that are right for them. Each trial has been summarised in accessible language to give a clear picture of its aims, what it involves and who to contact about the trial.
At Lazarex Cancer Foundation we improve the outcome of cancer care, giving hope, dignity and life to advanced stage cancer patients and the medically underserved by providing assistance with costs for FDA clinical trial participation, identification of clinical trial options, community outreach and engagement. We provide resources for cancer patients who have been told they have no other options, but who are not yet done with their journey in life and refuse to give up.
MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers through programs, education, and research. OsteoBites is a weekly webinar and podcast where Osteosarcoma Experts share their research, hope, and innovation.
Osteosarcoma Project by Count Me In is stewarded by the Broad Institute of MIT and Harvard, the Dana-Farber Cancer Institute and Emerson Collective. The Osteosarcoma Project has been designed and implemented collaboratively with osteosarcoma patients, advocates, caregivers, loved ones, cancer researchers, and clinicians. The goal of this project is to generate a large dataset that includes genomic, clinical, molecular, and patient reported information that can be shared with the biomedical community in order to accelerate discoveries and better therapies for this disease.
The Osteosarcoma Collaborative brings together data, researchers, patients and families to find new cures for osteosarcoma through advocacy, fundraising, education and awareness regarding the disease. They manage the Osteosarcoma Information Facebook page which was created for discussions focused on osteosarcoma treatment, clinical trials, and scientific research.
The mission of The Power of Will is simple – to support and enhance the lives of sarcoma patients and their loved ones. Established in honor of Will Hudson, The Power of Will is on a steadfast pursuit to change the narrative for sarcoma patients. They provide both educational tools and financial support opportunities because they have seen firsthand how overwhelming a sarcoma diagnosis can be.
The Hope Portal is a curated, community-driven directory of organizations in childhood cancer. Visit their website to find helpful organizations by selecting support categories, diagnoses, and/or locations that are relevant to you. The information on the Hope Portal is verified by members at the Coalition Against Childhood Cancer.
Osteosarcoma in Canines
Canine Osteosarcoma Background
The problem of cancer in pet dogs is significant. In the United States approximately 1 million pet dogs will be diagnosed with cancer each year. Cancers that develop in pet dogs share strong similarities with human cancer patients. Tumor initiation and progression are influenced by similar factors in both human and canine cancers, including age, nutrition, sex, reproductive status, and environmental exposures. The spectrum of cancers seen in pet dogs is as diverse as the cancers seen in human patients. Not surprisingly the genetic events that are understood to be associated with cancer development and progression in humans are also the same as those that occur in canine cancers. Furthermore, the conventional treatments that are effective in the treatment of human cancers are for the most part effective in the treatment of pet dogs cancers. The biological complexity of cancers in pet animals is high and emerges from a similar intra-tumoral (cell-to-cell) heterogeneity seen in human cancer patients. A natural consequence of this heterogeneity is the acquisition of resistance to therapy, recurrence of disease, and spread or metastasis to distant sites. In these ways the problem of cancer in pet dogs is identical to the problem of cancer in people.
Helping Patients on Both Sides of the Leash
An opportunity exists to help both pet dogs and people, particularly children with cancer. This opportunity integrates clinical trials that assess new drugs for the benefit of both canine and human cancer patients. The goal of this integrated effort is to speed the development of new cancer treatments by allowing questions to be answered in both the dog and the human rather than the human alone. Indeed, the formal integration of studies that include pet dogs with cancer has recently begun and is becoming a more common part of an innovative cancer drug development process.
Similarities in Canine and Human Osteosarcoma
Of the cancers that occur in both pet dogs and humans, osteosarcoma is perhaps the most similar. Osteosarcoma is the most common primary tumor of bone in both pet dogs and children. Pet dogs develop osteosarcoma at similar sites as pediatric patients, with identical microscopic features, and response to traditional treatment regimens such as surgery and chemotherapy. Most importantly, this cancer is associated with a high risk for spread from the bone to the lungs. An important difference between the species is that there are more than 10,000 new cases of osteosarcoma diagnosed in dogs each year, whereas there are approximately 800 osteosarcoma diagnoses made in people each year. New treatments are needed for this highly aggressive cancer in both species.
Canine Clinical Trial Resources
Find a Veterinary Oncologist in your area
Frequently Asked Questions
What is osteosarcoma?
Osteosarcoma is a type of bone cancer that originates in cells of the bone. The word “osteosarcoma” comes from the Greek words sarc, meaning fleshy substance, and oma, meaning growth. Osteo adds bone-like to the word sarcoma. It can occur anywhere along the skeleton, but the most common sites are in longer bones, for instance around the knee (distal femur and proximal tibia) and shoulder (proximal humerus).
How common is osteosarcoma?
Osteosarcoma is rare — only around 1,000 people are diagnosed in the United States each year. Osteosarcoma most commonly occurs in children, teenagers and young adults between the ages of 10 and 30. It is slightly more common in boys and young men. There is a peak incidence of osteosarcoma during the adolescent growth spurt. It is very rare in children under 5 years old.
What causes osteosarcoma?
The exact cause is still unknown. Osteosarcoma develops when healthy cells responsible for making new bone experience changes in their DNA. These DNA changes tell the cells to make abnormal bone. This results in a tumor that invades and destroys surrounding healthy bone and surrounding tissue.
Can osteosarcoma be prevented?
It cannot be prevented. However, there are certain risk factors to be aware of. Osteosarcoma risk factors include:
● Bone disorders (Paget’s disease and fibrous dysplasia)
● Exposure to radiation (for example, previous cancer treatment)
● Rare, inherited disorders (hereditary retinoblastoma, Bloom syndrome, Li-Fraumeni syndrome, Rothmund-Thomson syndrome and Werner syndrome)
What are the symptoms?
People with osteosarcoma may have a variety of symptoms, including:
● Pain in and around a bone that becomes persistent and severe over time
● Swelling near a bone
● Limping and/or inability to lift or use a limb
● Bone injury/fracture from minor trauma
If you or your child is experiencing any of the above symptoms, contact your doctor.
How is osteosarcoma diagnosed?
The diagnosis of osteosarcoma can only be definitively made with a biopsy of the affected area. Thanks to advanced imaging technology, doctors can see — with precision — where the abnormality is located in the body and help guide the biopsy. Once a biopsy confirms the diagnosis of osteosarcoma, a variety of other tests may be ordered to further determine the extent of the tumor. These may include:
● Computed tomography (CT) scan
● Magnetic resonance imaging (MRI)
● Positron emission tomography (PET) scan
● Additional blood tests
Can osteosarcoma spread?
Yes, osteosarcoma can metastasize, or spread, to other areas of the body, most commonly to the lungs. Osteosarcoma that spreads to the lungs happens when tumor cells travel to the lungs through the bloodstream. But since our blood always travels to the lungs to provide oxygen to our blood (and not all cancers spread to the lungs first), there must be additional reasons that osteosarcoma is so prone to lung metastases. This is an area of active research.
What are the treatment options for osteosarcoma?
Current therapy for osteosarcoma almost always includes the combination of a standard chemotherapy treatment and surgery. Most commonly, chemotherapy is given for several months before surgery and is continued after the patient has recovered from their surgery. The type of surgery performed can vary, but usually includes limb-preservation surgery. Following recovery from surgery, patients begin physical rehabilitation as part of their recovery process.
What should I know about clinical trials?
Clinical trials are available, if and when a patient recurs, following standard treatment. These trials provide patients access to novel treatment methods and drug therapies that are being developed to treat osteosarcoma. Depending on your individual case, you may be eligible to participate in one. The Osteosarcoma Institute is pleased to connect you with a free and confidential clinical trial matching service. Most clinical trials for osteosarcoma include newer “targeted therapy drug” or combinations with immunotherapy.
What are treatment side effects?
With any cancer treatment, there are side effects. This is also true for osteosarcoma treatment. Surgery often involves use of an internal prosthesis and rarely an external prosthesis. Physical therapy will be provided as you heal to help guide rehabilitation and ensure strength and movement are regained in the safest way possible. Chemotherapy side effects can include hair loss, nausea, fatigue, weakness, loss of appetite and weight loss. These side effects will resolve when chemotherapy is completed.
What is the outlook for people with osteosarcoma?
The outlook depends on many factors, including the location and size of the tumor, whether the cancer has spread and the person’s age and overall health. For more information on osteosarcoma survival rates, click here.
Why is more research needed?
There have been no improvements in survival of osteosarcoma patients for more than 30 years. Osteosarcoma is complex, and more research is needed. For a brief history of osteosarcoma treatment, click here. Areas of research include gene therapy, targeted drug therapy and immunotherapy.
from the Director’s Desk
Each quarter the Osteosarcoma Institute Director, Dr. Lee Helman, shares a reputable reading reccomendation to guide our supporters through learnings, breakthroughs, and updates in osteosarcoma and childhood cancer.
Current approaches to management of bone sarcoma in adolescent and young adult patients
Advancing therapy for osteosarcoma
Doctors diagnose advanced cancer—in a dinosaur